NEW YORK – Illumina said on Tuesday that it has partnered with Chinese genomics firm HaploX to launch a domestically produced sequencer, NextSeq 2000Dx-Cn-Hap, in China.
"This marks a new stage in the strategic partnership between the two companies," Illumina said in a statement. "In the future, Illumina and HaploX will take the localized manufacturing of high-end life science instruments as a new starting point, focus on scientific research and innovation, and leverage the advantages of the Guangdong-Hong Kong-Macao Greater Bay Area."
HaploX, based in Shenzhen, said it has provided genetic testing services to hundreds of hospitals, biopharmaceutical companies, research institutes, health examination centers, insurance companies, and local governments across the country.
The firm said it focuses on genetic sequencing, liquid biopsy testing, bioinformatics, and big data analytics. Its Shenzhen laboratory is CLIA-certified and CAP-accredited.
In 2018, HaploX closed a $32 million Series A-plus financing round that included investors SB China Venture Capital and Kexin Capital.